Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Biotech’s Year-End To-Do List

TheMotleyFool

0 0

Biotech’s Year-End To-Do ListPhoto, wide shot, wide-angle lens, Biotech company, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Sebastião Salgado: https://img.theapi.app/temp/80e18bfd-1ff8-4487-af62-1cdb7de1ceb6.png

Before we ring in 2020, December will be ripe for swings in biotech stock prices. 2019 started strong, waned, and then regained momentum amid a slew of successful clinical trial results, several acquisition announcements, and positive drug approval decisions that came often months ahead of the U.S. Food and Drug Administration's own deadlines.

Additionally, the looming unknown of who will be the next head of the FDA was answered when President Trump nominated Dr. Stephen Hahn this week.

Image Source: Getty Images.

Source Fool.com

Like: 0

PBYI

Share